Kiniksa Pharmaceuticals (KNSA)
(Real Time Quote from BATS)
$25.76 USD
+0.32 (1.26%)
Updated Aug 15, 2024 09:42 AM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Kiniksa Pharmaceuticals, Ltd. [KNSA]
Reports for Purchase
Showing records 81 - 100 ( 112 total )
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
2Q19; KPL-716 Update Shows Positive Impact on Pruritus
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Programs Continue to Advance; KPL-404 to Enter Clinic in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Rilo on the Rise with Ph 2 Update; KOL Feedback Positive
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Phase 3 for Rilonacept Running, ?716 Updates in H2:19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kiniksa Pharmaceuticals, Ltd.
Industry: Medical - Biomedical and Genetics
Rilonacept Shows Encouraging Ph 2 Readout, Moves into Pivotal Ph 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D